Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

Pregnant women who get the RSV shot late in the pregnancy can pass along the antibodies to their infant. This is an option ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Opens in a new tab or window The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years and older, as well as for 60- to 74-year ...

Opens in a new tab or window During last year's respiratory virus season, newly approved vaccines for respiratory syncytial virus (RSV) were effective in preventing associated hospitalizations and ...

RSV is a significant public health concern for vulnerable populations, especially the elderly and newborns. Researchers estimate that nearly every child will be infected by the age of two. While ...

Pediatricians across the Mid-South say upper respiratory infections are surging right now, especially among young children.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Respiratory syncytial virus (RSV) is an infection that can be passed from children to adults. While most healthy adults with RSV infection usually can be treated at home, older infected adults may be ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...